证券代码：002900 证券简称：哈三联 公告编号：2025-041 哈尔滨三联药业股份有限公司 关于公司药品通过一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的药品补充申请批准通知书，公司药品注射用盐酸地尔硫䓬通过 仿制药质量和疗效一致性评价（以下简称"一致性评价"）。具体情况如下： | 药品名称 | 规格 | 注册分类 | 上市许可持有人 | 审批结论 | | --- | --- | --- | --- | --- | | 注射用盐酸地 | 10mg | 化学药品 | 哈尔滨三联药业 | 经审查，本品通过仿制药质 | | 尔硫䓬 | | | 股份有限公司 | 量和疗效一致性评价。 | 注射用盐酸地尔硫䓬用于治疗①阵发性室上性心动过速、心房颤动或心房扑 动。用于阵发性室上性心动过速快速转化为窦性节律；用于暂时性控制心房颤动 或心房扑动过程中过快的心室率。②手术时异常高血压的急救处置。③高血压急 症。④不稳定心绞痛。 截止目前，持有该产品生产批文的厂家较多， ...

Market Overview - A-shares maintained a narrow fluctuation on July 16, with the Shanghai Composite Index closing at 3503.78 points, down 0.03% [1] - The Shenzhen Component Index and the ChiNext Index both fell by 0.22% to 10720.81 points and 2230.19 points, respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was 146.19 billion yuan, a decrease of over 170 billion yuan from the previous day [1] Sector Performance - Financial stocks collectively declined, while the steel, non-ferrous metals, and coal sectors showed weakness [1] - The automotive supply chain stocks surged, with companies like Rongtai Co., Fuda Co., and Zhejiang Rongtai hitting the daily limit [1] - The innovative drug concept saw significant activity, with stocks like Guosheng Tang and Iwu Biotech rising approximately 16% [5][6] - The humanoid robot concept remained hot, with companies like Shangwei New Materials achieving a six-day limit increase [2][4] Notable Company Movements - Huadian New Energy, which debuted on the Shanghai main board, closed up 125.8%, reaching a market value of over 300 billion yuan at one point [1] - Weiyali, a Hong Kong-based electronic component distributor, saw its stock surge by 288% upon resuming trading, with an intraday increase exceeding 900% [1] Humanoid Robot Sector Insights - The humanoid robot industry is in its early stages, with significant growth expected in the next 3 to 5 years across various applications [4] - The current phase is described as the "dawn" of humanoid robot industrialization, with mass production and large-scale application becoming feasible [4] - Cost reduction is crucial for the widespread adoption of humanoid robots, and companies that master core component technologies are recommended for investment [4] Innovative Drug Sector Insights - The innovative drug sector experienced strong gains, with several companies hitting the daily limit [5][6] - The recent launch of the 11th batch of national drug centralized procurement is expected to impact the market, focusing on mature "old drugs" rather than innovative drugs [7] - The introduction of measures to support the high-quality development of innovative drugs indicates a growing role for commercial insurance in the healthcare system [7] Pet Economy Sector Insights - The pet economy concept gained traction, with companies like Weike Technology rising over 10% [8] - The pet food sector is viewed as a growing market with significant long-term growth potential, particularly for domestic brands [8]

Core Viewpoint - The generic drug consistency evaluation concept has shown a significant increase, with a rise of 2.67%, making it the second-highest gaining sector on the market as of July 16 [1][2]. Market Performance - The generic drug consistency evaluation sector saw 119 stocks increase in value, with notable performers including: - Guangsheng Tang, which rose by 16.55% - Lai Mei Pharmaceutical, which increased by 8.48% - Han Yu Pharmaceutical, which gained 6.41% [1][2]. - Conversely, the sector also experienced declines, with *ST Su Wu dropping by 5.02%, Nanxin Pharmaceutical by 3.17%, and Kelun Pharmaceutical by 0.95% [1]. Capital Flow - The sector attracted a net inflow of 2.102 billion yuan from major funds, with 77 stocks receiving net inflows. Five stocks had net inflows exceeding 100 million yuan, led by Qianhong Pharmaceutical with 227 million yuan [2][3]. - Other significant net inflows were observed in: - Han Yu Pharmaceutical with 166 million yuan - Ha San Lian with 155 million yuan - Run Du Shares with 145 million yuan [2]. Stock Performance Metrics - The top stocks in terms of net inflow ratio included: - Run Du Shares at 42.20% - Ha San Lian at 34.99% - Zhejiang Zhen Yuan at 29.25% [3]. - The performance of stocks within the sector varied, with Qianhong Pharmaceutical showing a daily increase of 9.98% and a turnover rate of 14.39% [3][4].

Group 1 - The innovative drug sector remains active, with companies such as Wanbangde (002082) and Hasanlian (002900) seeing significant market activity in the afternoon session [1] - Other companies like Lizhu Group (000513), Jiankangyuan (600380), and Jinshiyao (300434) are also experiencing upward movement in their stock prices [1] - There is a notable influx of dark pool capital into these stocks, indicating potential investor interest and market dynamics [1]

哈尔滨三联药业股份有限公司（以下简称"公司"）因业务经营拓展的需求， 增加"食品用塑料包装容器工具制品生产"的经营范围。同时，根据《公司法》 等有关规定，公司对《公司章程》相关条款进行修订。公司分别于 2025 年 6 月 25 日召开的第四届董事会第二十二次会议及 2025 年 7 月 11 日召开的 2025 年第 一次临时股东大会，审议通过了《关于变更公司经营范围及修订<公司章程>的 议案》。上述具体内容详见公司在中国证监会指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 证券代码：002900 证券简称：哈三联 公告编号：2025-040 哈尔滨三联药业股份有限公司 关于完成经营范围变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经营范围： 许可项目：药品生产；药品批发；药品零售；药品委托生产；药品进出口； 化妆品生产；食品生产；饮料生产；食品销售；食品互联网销售；保健食品生产； 第二类医疗器械生产；第三类医疗器械生产；第三类医疗器械经营；消毒剂生产 （不含危险化学品）；消毒器械生产；消毒 ...

Group 1 - New Yi Sheng expects a net profit increase of 327.68%-385.47% for the first half of 2025, reaching between 37 billion to 42 billion yuan, driven by growth in AI-related computing power demand and product structure optimization [2][4] - Xinghui Entertainment plans to sell 99.66% of its stake in the Spanish club Espanyol for 1.3 billion euros, with half of the payment in cash and the other half in shares [3] - *ST Yushun intends to acquire 100% of three companies for a total of 33.5 billion yuan, aiming to diversify its business into data center infrastructure services and related products [4] Group 2 - Salted Fish plans to reduce its shareholding by up to 2.04%, with a major shareholder intending to sell 5,455,572 shares [5] - Lian Microelectronics expects a net loss of approximately 1.21 billion yuan for the first half of 2025 [6] - Meinian Health anticipates a net loss of 1.92 billion to 2.36 billion yuan for the first half of 2025, with revenue expected to decline by 0.12%-5.83% [7] Group 3 - Chengdi Xiangjiang forecasts a net profit of 28 million to 42 million yuan for the first half of 2025, marking a turnaround from a loss of 69.29 million yuan in the previous year [8] - Jinpu Titanium plans to acquire 100% of Nanjing Lide Oriental Rubber and Plastic Technology Co., Ltd., with stock resuming trading after the announcement [9] - Bohai Leasing expects a net loss of 1.8 billion to 2.4 billion yuan for the first half of 2025 due to goodwill impairment from a subsidiary's asset sale [10] Group 4 - Foton Motor anticipates a net profit increase of approximately 87.5% for the first half of 2025, reaching about 777 million yuan [11] - Shenwan Hongyuan expects a net profit growth of 92.66%-111.46% for the first half of 2025, estimating profits between 4.1 billion to 4.5 billion yuan [12] - Ganfeng Lithium predicts a net loss of 5.5 billion to 3 billion yuan for the first half of 2025, an improvement from a loss of 7.6 billion yuan in the previous year [13] Group 5 - Suzhou Planning intends to acquire 100% of Beijing Dongjin Aviation Technology Co., Ltd., with stock resuming trading after the announcement [14] - Xiangyang Bearing expects a net loss of approximately 13 million yuan for the first half of 2025, slightly worse than the previous year's loss [15] - Tianqi Lithium forecasts a net profit of 0 to 1.55 billion yuan for the first half of 2025, a significant improvement from a loss of 5.2 billion yuan in the previous year [16] Group 6 - Shandong Gold anticipates a net profit increase of 84.3%-120.5% for the first half of 2025, estimating profits between 2.55 billion to 3.05 billion yuan [17] - Yunnan Geology expects a net profit of 16 million to 23 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [18] - Four-dimensional Map expects a net loss of 319 million to 268 million yuan for the first half of 2025, with revenue growth of 3.07%-14.30% [19] Group 7 - Tangrenshen anticipates a net loss of 54 million to 69 million yuan for the first half of 2025, a significant decline from the previous year's profit [20] - Changbai Mountain expects a net loss of 2.58 million to 1.58 million yuan for the first half of 2025, with revenue decreasing by approximately 7.48% [21] - Jiu Gui Jiu predicts a net profit of 8 million to 12 million yuan for the first half of 2025, a decline of 90.08%-93.39% compared to the previous year [22] Group 8 - Hengsheng Electronics expects a net profit increase of 740.95% for the first half of 2025, estimating profits around 251 million yuan [23] - Qixia Construction anticipates a net profit of 5.5 million to 8 million yuan for the first half of 2025, driven by increased project completions [24] - Poly Development expects a net profit decrease of 63.15% for the first half of 2025, estimating profits around 27.35 billion yuan [25] Group 9 - Anyuan Coal anticipates a net loss of 259 million to 310 million yuan for the first half of 2025, worsening from the previous year's loss [26] - Zhonghua Equipment plans to acquire 100% of Yiyang Rubber Machine and Beihua Machine, with stock suspension expected for no more than 10 trading days [27] - Bayi Steel expects a net loss of 650 million to 700 million yuan for the first half of 2025, primarily due to weak market conditions [28] Group 10 - Yuegui Co. anticipates a net profit increase of 58.67%-77.12% for the first half of 2025, estimating profits between 215 million to 240 million yuan [29] - Dalian Friendship expects a net loss of 38 million to 30 million yuan for the first half of 2025, with revenue impacted by tax-related issues [30] - Hangfa Power expects a net profit decrease of 84.53%-86.55% for the first half of 2025, estimating profits around 80 million to 92 million yuan [31] Group 11 - Dongfang Zirconium anticipates a net profit increase of 141.77%-156.80% for the first half of 2025, estimating profits between 25 million to 34 million yuan [32] - Hangzhou Steel expects a net profit decrease of 2% from a major shareholder's planned reduction [33] - Jingao Technology predicts a net loss of 2.5 billion to 3 billion yuan for the first half of 2025, worsening from the previous year's loss [34] Group 12 - Shanshan Co. expects a net profit increase of 810.41%-1265.61% for the first half of 2025, estimating profits between 160 million to 240 million yuan [35] - Guocheng Mining anticipates a net profit increase of 1046.75%-1174.69% for the first half of 2025, estimating profits between 493 million to 548 million yuan [36] - Jindi Group expects a net loss of 3.4 billion to 4.2 billion yuan for the first half of 2025, with significant declines in revenue [37] Group 13 - Founder Securities anticipates a net profit increase of 70%-80% for the first half of 2025, estimating profits between 22.96 billion to 24.32 billion yuan [38] - Hasi Lian expects a net loss of 98 million to 80 million yuan for the first half of 2025, a significant decline from the previous year [39] - Lanhua Ketech expects a net profit decrease of 89.12%-92.75% for the first half of 2025, estimating profits between 40 million to 60 million yuan [40] Group 14 - Shanxi Securities anticipates a net profit increase of 58.17%-70.72% for the first half of 2025, estimating profits between 5.04 billion to 5.44 billion yuan [41] - Xinda Real Estate expects a net loss of 3.5 billion to 3.9 billion yuan for the first half of 2025, with significant declines in revenue [42] - Xiangcai Co. anticipates a net profit increase of 63.64%-118.19% for the first half of 2025, estimating profits between 12 million to 16 million yuan [43] Group 15 - Longi Green Energy expects a net loss of 2.4 billion to 2.8 billion yuan for the first half of 2025, despite an increase in sales volume [44] - Wentai Technology anticipates a net profit increase of 178%-317% for the first half of 2025, estimating profits between 390 million to 585 million yuan [45] - Ruida Futures expects a net profit increase of 50.56%-83.15% for the first half of 2025, estimating profits between 206 million to 251 million yuan [46] Group 16 - Debang Co. anticipates a net profit decrease of 84.26%-87.86% for the first half of 2025, estimating profits between 40 million to 52 million yuan [47] - Jin Yi Culture expects a net loss of 20 million to 32 million yuan for the first half of 2025, a significant decline from the previous year [48] - Hongdian Film expects a net profit increase of 103.55%-160.09% for the first half of 2025, estimating profits between 180 million to 230 million yuan [49] Group 17 - Qiaqia Food anticipates a net profit decrease of 71.05%-76.25% for the first half of 2025, estimating profits between 80 million to 97.5 million yuan [50] - Guotai Haitong expects a net profit increase of 205%-218% for the first half of 2025, estimating profits between 15.283 billion to 15.957 billion yuan [51] - Xining Special Steel expects a net loss of approximately 234 million yuan for the first half of 2025, with revenue impacted by low steel prices [52]

[Harbin Sanlian Pharmaceutical Co., Ltd. 2025 H1 Earnings Forecast](index=1&type=section&id=%E5%93%88%E5%B0%94%E6%BB%A8%E4%B8%89%E8%81%94%E8%8D%AF%E4%B8%9A%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) [H1 2025 Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a significant year-over-year decline and a net loss for the first half of 2025 H1 2025 Performance Forecast | Item | Current Period (H1 2025) | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Loss: RMB 98.00 million - 80.00 million | Profit: RMB 26.27 million | | YoY Change | Decline: 473.03% - 404.52% | - | | **Net Profit Excl. Non-recurring Items** | Loss: RMB 95.00 million - 77.00 million | Profit: RMB 21.13 million | | YoY Change | Decline: 549.50% - 464.33% | - | | **Basic Earnings Per Share (EPS)** | Loss: RMB 0.30/share - 0.24/share | Profit: RMB 0.08/share | [Communication with the Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The company clarifies that the financial data in this earnings forecast has not been audited by an accounting firm - The financial data in this earnings forecast **has not been audited** by an accounting firm[4](index=4&type=chunk) [Explanation of Performance Fluctuation](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The shift from profit to loss is driven by lower product prices, increased depreciation, and inventory provisions [Decline in Sales Prices](index=1&type=section&id=3.1%20%E9%94%80%E5%94%AE%E4%BB%B7%E6%A0%BC%E4%B8%8B%E9%99%8D) Product selling prices fell due to national procurement policies and market competition, reducing revenue and gross profit - Product sales prices declined due to national drug procurement policies and intensified market competition[6](index=6&type=chunk) H1 2025 Forecasted Impact of Price Decline | Metric | H1 2025 Forecast | YoY Change | | :--- | :--- | :--- | | Revenue | RMB 413 million | Decrease of RMB 110 million | | Gross Profit | - | Decrease of RMB 107 million | [Operating Costs and Period Expenses](index=2&type=section&id=3.2%20%E8%90%A5%E4%B8%9A%E6%88%90%E6%9C%AC%E5%8F%8A%E6%9C%9F%E9%97%B4%E8%B4%B9%E7%94%A8) Depreciation and financial expenses increased, while selling and R&D expenses decreased - Operating costs remained relatively stable, but **depreciation expenses increased significantly by over RMB 14 million** YoY due to the capitalization of construction projects[7](index=7&type=chunk) - Overall period expenses decreased, with a combined **reduction of over RMB 27 million in selling and R&D expenses**, though financial expenses rose by over RMB 12 million[7](index=7&type=chunk) [Provision for Inventory Impairment](index=2&type=section&id=3.3%20%E8%AE%A1%E6%8F%90%E5%AD%98%E8%B4%A7%E5%87%8F%E5%80%BC%E5%87%86%E5%A4%87) An inventory impairment provision of approximately RMB 11 million is expected for H1 2025 due to lower product selling prices - An **inventory impairment provision of approximately RMB 11 million** is expected for H1 2025 due to declining sales prices[7](index=7&type=chunk) [Other Relevant Information](index=2&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company states this forecast is a preliminary estimate and advises investors to refer to the final H1 2025 report - This earnings forecast is a preliminary estimate by the finance department; **final data will be in the official H1 report**[8](index=8&type=chunk)

证券代码：002900 证券简称：哈三联 公告编号：2025-038 哈尔滨三联药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案或修改议案的情况；本次股东大会上无新提议 案提交表决； 2、本次股东大会不涉及变更前次股东大会决议的情况； 3、本次股东大会因涉及审议影响中小投资者利益的重大事项，公司将对中小 投资者表决情况进行单独计票。中小投资者是指以下股东以外的其他股东： （1）上市公司的董事、监事、高级管理人员； （2）单独或者合计持有上市公司 5%以上股份的股东。 一、会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 7 月 11 日（周五）16:00； （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 7 月 11 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 7 月 11 日 9:15-15:00 期间任意时间。 ...

北京市中伦律师事务所（以下简称"本所"）作为哈尔滨三联药业股份有限 公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2025 年第一次临时股东大会（以下简称"本次股东大会"）。本所律师根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）》《上市公司股东会规则》等相关法律、法规、规范性 文件及《哈尔滨三联药业股份有限公司章程》（以下简称"《公司章程》"）的 规定，对本次股东大会进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 法律意见书 北京市中伦律师事务所 关于哈尔滨三联药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：哈尔滨三联药业股份有限公司 即其已提供了本所律师认为 ...

300318 博晖创新 6.37 5.19 3220.45 沪指7月8日上涨0.70%，申万所属行业中，今日上涨的有29个，涨幅居前的行业为通信、电力设备，涨 幅分别为2.89%、2.30%。医药生物行业今日上涨0.31%。跌幅居前的行业为公用事业、银行，跌幅分别 为0.37%、0.24%。 资金面上看，两市主力资金全天净流入154.50亿元，今日有14个行业主力资金净流入，电子行业主力资 金净流入规模居首，该行业今日上涨2.27%，全天净流入资金74.37亿元，其次是电力设备行业，日涨幅 为2.30%，净流入资金为36.78亿元。 主力资金净流出的行业有17个，公用事业行业主力资金净流出规模居首，全天净流出资金22.97亿元， 其次是医药生物行业，净流出资金为22.85亿元，净流出资金较多的还有国防军工、银行、商贸零售等 行业。 医药生物行业今日上涨0.31%，全天主力资金净流出22.85亿元，该行业所属的个股共474只，今日上涨 的有337只，涨停的有6只；下跌的有123只，跌停的有1只。以资金流向数据进行统计，该行业资金净流 入的个股有191只，其中，净流入资金超亿元的有5只，净流入资金居首的是昭衍新药 ...